[Report] In Vitro Diagnostics Market Research ,Trends, Analysis

Abstract

This brand new report examines the commercial prospects for in vitro diagnostics (IVD) in the global healthcare market. Technological solutions are playing an increasingly important role in both clinical practice and pharmaceutical R&D - increasing safety, speeding up clinical development and facilitating regulatory acceptance. Furthermore, current developments in diagnostics - especially molecular diagnostics - are paving the way towards the long-held goal of personalised medicine, to the benefit of patients, companies and healthcare providers. Developments in IVD also receive encouraging support from regulators such as the FDA. Visiongain believes that some of the greatest opportunities ever available for diagnostics companies are now there to be seized, with important sales, licensing and partnership developments from the present onwards.

Importantly, this report also covers theranostics, a fusion of drug therapy and diagnostics to optimise efficacy and safety, as well as streamlining drug development. Combining a drug with a diagnostic process or test is also known as companion diagnostics, integrated medicine, pharmacodiagnostics and Dx/Rx partnering. This emerging field is generating strong interest from the healthcare industry and regulatory bodies, with the associated market expanding as the importance of theranostics is recognised, especially in cancer.

Our new In Vitro Diagnostics Market Report & Analysis 2008-2023 report examines the market for in vitro diagnostic solutions critically, through comprehensive primary and secondary research. Importantly, visiongain discusses IVD in the context of the wider healthcare market, with a strong emphasis on theranostics and related molecular diagnostics/medicine. In addition to consultation with experts in industry - including full interview transcripts - this research involved a detailed study of relevant documents, industrial reports and current developments. Vitally, visiongain applied unique in-house forecasting techniques and analysis of drivers and restraints. The result is a totally independent in-depth market-based report with detailed analyses and informed opinion.

In particular, this report concentrates on the following essential aspects of the in vitro diagnostics sector:

Technologies that drive the IVD sector, including those related to theranostics
Key industrial players in IVD - both established and emerging - including partnerships
Forecasts of the global IVD market from 2008-2023 - including those of principal market segments, both by disease area and technology
Forecasts for IVD sales in leading national markets, including China and India
Forecasts for theranostic applications - including therapeutic areas - from 2008-2023
Drivers and opportunities in the IVD sector
Restraints and threats in the IVD sector
Assessments of relevant business models, technological solutions and associated issues
Coverage of future trends in IVD and theranostics
Insight from a comprehensive survey with relevant experts

Why you should buy this report:

To receive a comprehensive analysis of the prospects for IVD from 2008-2023, including sales by disease area, technology and country
To discover predicted revenues, growth rates and other key metrics for theranostic solutions from 2008-2023
To receive the views of experts in the IVD sector regarding current and future trends
To determine the forces that influence the market for IVD:
Competition
Drivers
Restraints
Strengths, weaknesses, opportunities and threats
To find out where the IVD market is heading - both technologically and commercially

Visiongain predicts that the markets for IVD and theranostics will exhibit strong growth in revenues from 2008-2023, with significant investments being made by far-sighted companies and healthcare providers. Although still in its early stages of commercial development, molecular diagnostics will increasingly gain acceptance from stakeholders in healthcare. You should be benefiting from this opportunity. You and your company can benefit as a result, gaining early market prominence from high-value products. You cannot afford to ignore current developments in diagnostics, especially as personalised medicine becomes an inevitable reality.